Literature DB >> 9228711

Effectiveness of leukocyte filters in reducing tumor cell contamination after intraoperative blood salvage in lung cancer patients.

P Perseghin1, M Viganò, G Rocco, C Della Pona, A Buscemi, A Rizzi.   

Abstract

OBJECTIVES: In an effort to reduce allogeneic blood transfusions in patients undergoing elective surgery for lung cancer, we investigated the effectiveness of a method of processing shed blood with an automated device for intra operative blood salvage (IOBS) and filtration with a 3rd-generation polyester filter to remove tumor cells.
METHODS: Sixteen patients were operated on for different types of lung cancer. We searched for malignant cells in pre- and postprocessed shed blood employing density gradient centrifugation, staining of cytospins with hematoxylin-eosin, and antibodies to human cytokeratins.
RESULTS: In 9 out of 16 cases (56%), neoplastic cells were detected in prefiltration samples, but none were found in postfiltration cytospins.
CONCLUSION: IOBS combined with appropriate filtration could be a very useful and safe tool in reducing allogeneic blood transfusion in cancer patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9228711     DOI: 10.1046/j.1423-0410.1997.7240221.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  18 in total

Review 1.  Transfusion of post-operative shed blood: laboratory characteristics and clinical utility.

Authors:  M Muñoz; J J García-Vallejo; M D Ruiz; R Romero; E Olalla; C Sebastián
Journal:  Eur Spine J       Date:  2004-05-08       Impact factor: 3.134

2.  Peri-operative filtration of disseminated cytokeratin positive cells in patients with colorectal liver metastasis.

Authors:  Nils R Frühauf; Sabine Kasimir-Bauer; Klaus Görlinger; Hauke Lang; Christian P Kaudel; Gernot M Kaiser; Karl J Oldhafer; Christoph E Broelsch
Journal:  Langenbecks Arch Surg       Date:  2004-11-19       Impact factor: 3.445

3.  Recommendations for the transfusion management of patients in the peri-operative period. II. The intra-operative period.

Authors:  Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2011-04       Impact factor: 3.443

Review 4.  Intra-operative cell salvage: a fresh look at the indications and contraindications.

Authors:  Stephen A Esper; Jonathan H Waters
Journal:  Blood Transfus       Date:  2011-01-13       Impact factor: 3.443

5.  Does autologous blood transfusion during liver transplantation for hepatocellular carcinoma increase risk of recurrence?

Authors:  Raphael Lc Araujo; Carlos Andrés Pantanali; Luciana Haddad; Joel Avancini Rocha Filho; Luiz Augusto Carneiro D'Albuquerque; Wellington Andraus
Journal:  World J Gastrointest Surg       Date:  2016-02-27

6.  Are we ready for the use of intraoperative salvaged blood in metastatic spine tumour surgery?

Authors:  Naresh Kumar; Qasim Ahmed; Victor K M Lee; Aye Sandar Zaw; Raymond Goy; Hee Kit Wong
Journal:  Eur Spine J       Date:  2015-07-19       Impact factor: 3.134

7.  Safety of Intraoperative Cell Salvage in Cancer Surgery: An Updated Meta-Analysis of the Current Literature.

Authors:  Thomas Frietsch; Andrea U Steinbicker; Audrey Horn; Matthes Metz; Gerald Dietrich; Markus A Weigand; Jonathan H Waters; Dania Fischer
Journal:  Transfus Med Hemother       Date:  2022-05-11       Impact factor: 4.040

8.  Blood salvage and cancer surgery: should we do it?

Authors:  Jonathan H Waters; Albert D Donnenberg
Journal:  Transfusion       Date:  2009-10       Impact factor: 3.157

9.  Intraoperative cell salvage in metastatic spine tumour surgery reduces potential for reinfusion of viable cancer cells.

Authors:  Naresh Kumar; Aye Sandar Zaw; Bee Luan Khoo; Sayantani Nandi; Zhangxing Lai; Gurpal Singh; Chwee Teck Lim; Jean Paul Thiery
Journal:  Eur Spine J       Date:  2016-03-07       Impact factor: 3.134

Review 10.  Controlled hypotension: a guide to drug choice.

Authors:  Christian-Serge Degoute
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.